Networking

EFCCA Magazine 3/2024

We’re excited to present the latest issue of the EFCCA Magazine, now with a refreshed design! Inside, you’ll find an exclusive interview with Professor James Lee, who shares insights on his groundbreaking research into the causes of Inflammatory Bowel Disease (IBD).

Read time: 1 min

GA 2024 - Brussels

From 7 to 9 June 2024, Brussels hosted the European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA) General Assembly, representing a significant event for our organisation.
 

Read time: 2 mins

EFCCA PROJECTS DIGEST Newsletter

We are delighted to present to you the EFCCA PROJECTS DIGEST. This newsletter will include information regarding the 5 Horizon Europe projects, 2 Horizon 2020 projects, and other projects that EFCCA is presently engaged in. The PROJECTS DIGEST  will be published every 2-3 months, and we trust it will serve as a valuable resource for delving deeper into our ongoing research initiatives.

Read time: 1 min

Early Real-World Outcomes with Filgotinib in Patients with Ulcerative Colitis: A Prospective, Observational Study (GALOCEAN)

Early Real-World Outcomes with Filgotinib in Patients with Ulcerative Colitis: A Prospective, Observational Study (GALOCEAN)

October 2024

This study investigates the real-world effectiveness of Filgotinib (FIL), an oral JAK1 preferential inhibitor, in patients with ulcerative colitis (UC). While the clinical efficacy of FIL has been established in the SELECTION trial, real-world data has been limited.

Read time: 1 min